Vir: Data Shows Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant

LONDON (dpa-AFX) - Vir Biotechnology Inc. (VIR) said pre-clinical data suggested that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed

Related Keywords

United States ,London ,City Of ,United Kingdom , ,Glaxosmithkline ,Vir Biotechnology Inc ,Data ,Shows ,Otrovimab ,Etains ,Neutralizing ,Activity ,Against ,Micron ,Ubvariant ,